
About Castle Creek Biosciences
Castle Creek Biosciences is a Healthcare company based in Exton (United States) founded in 2018. Gene therapy platform for rare disease treatments is developed. Castle Creek Biosciences has raised $192.8 million across 4 funding rounds from investors including Fidelity Investments, Paragon Biosciences and Horizon Tech Finance. The company has 41 employees. Its focus areas include Life Sciences, Rare Diseases, Drugs and Dermatological Diseases. Its legal entity is CASTLE CREEK BIOSCIENCES, LLC. Its competitors include Ironwood Pharma, Castle Creek Pharma and VeraDermics; 3 of its 3 listed competitors have raised funding.
Company details
Castle Creek Biosciences was founded in 2018 and is headquartered in Exton, United States. A gene therapy platform based on autologous fibroblasts derived from patient skin cells is offered for rare skin and connective tissue disorders, including epidermolysis bullosa and localized scleroderma. Clinical development includes FCX-007 in phase 3 trials, with FCX-013 and CCP-020 in phase 2. Operations focus on dermatology and related rare disease areas.
- Headquarters Exton, United States
- Employees 41
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website castlecreekbio.com
- Social LinkedIn X Facebook
- Legal Name Castle Creek Biosciences, Llc
- Total Equity Funding$192.8M (USD)
in 4 rounds
- Latest Funding Round$112.8M (USD), Series D
Jan 2022
- InvestorsFidelity Investments
& 3 more
- Employee Count41
Funding Insights of Castle Creek Biosciences
Castle Creek Biosciences has successfully raised a total of $192.8M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $112.8 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $192.8M
- Total Rounds 4
- Last Round Series D β $112.8M
- First Round $20M
(Mar 2020)
- Investors Count 4
All 4 funding rounds of Castle Creek Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $112.8M | Series D | β | Fidelity Investments, Valor Equity Partners | β |
| Jun 2021 | $25M | Series C | β | β | β |
| Mar 2020 | $55M | Series C | β | Paragon Biosciences | |
| Mar 2020 | $20M | Debt – Conventional | β | β |
4 investors in total: 4 institutional.
Investors in Castle Creek Biosciences
Castle Creek Biosciences has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paragon Biosciences and Horizon Tech Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm | valorep.com | Chicago, United States | ||
Structured debt is provided to life sciences and technology firms. | 2004 | horizontechfinance.com | Farmington, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Advisory services are provided to healthcare companies. | 2010 | paragonbiosci.com | Chicago, United States |
Investor details for Castle Creek Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Castle Creek Biosciences
12 people are tracked at Castle Creek Biosciences (6 in leadership, 1 in board & advisors, 5 in team); the tracked headcount is 41.
| Name | Role | Group |
|---|---|---|
Matthew Gantz | Chairman & CEO | Leadership |
Mayo Pujols | Chief Operating Officer | Leadership |
Matthew Crabtree | Senior Director, Finance | Leadership |
David Chu | Chief Medical Officer | Leadership |
Karen Casey | Director, Corporate Communications | Leadership |
Shelby Stevens | Director Of Manufacturing | Leadership |
M. Peter Marinkovich | Scientific Advisor | Board & advisors |
Savita Mehra | AVP, Quality Assurance | Team |
Forrest Jacobs | Desktop Support Manager | Team |
Lauren Stephenson | Quality Assurance Manager | Team |
Nicholas Bastian | Manufacturing Supervisor | Team |
Katie Dungca | Supervisor PCR Lab | Team |
Complete people profiles for Castle Creek Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Castle Creek Biosciences
3 dated milestones of Castle Creek Biosciences across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Castle Creek Biosciences is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series D, of $112.8M.
Competitors of Castle Creek Biosciences
Castle Creek Biosciences has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Castle Creek Pharma and VeraDermics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| veradermics.com | 2020 | San Antonio, United States | $262.71M | Drug-delivery platforms for pediatric wart treatments are developed. |
Detailed competitors of Castle Creek Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Castle Creek Biosciences
The website of Castle Creek Biosciences (castlecreekbio.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 37.9% vs previous month
Top companies in Rare Diseases
3 companies that operate in the same segment as Castle Creek Biosciences (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Castle Creek Biosciences
Complete news archive for Castle Creek Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Castle Creek Biosciences
Castle Creek Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Castle Creek Biosciences is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Castle Creek Biosciences is a funded company, having raised a total of $192.8M across 4 funding rounds to date. The company's 1st funding round was a Series C of $55M, raised on Mar 2020.
Castle Creek Biosciences has 41 employees.
Castle Creek Biosciences was founded in 2018 and is headquartered in Exton, United States. A gene therapy platform based on autologous fibroblasts derived from patient skin cells is offered for rare skin and connective tissue disorders, including epidermolysis bullosa and localized scleroderma. Clinical development includes FCX-007 in phase 3 trials, with FCX-013 and CCP-020 in phase 2. Operations focus on dermatology and related rare disease areas.
Castle Creek Biosciences's top competitors include Ironwood Pharma, VeraDermics and Castle Creek Pharma.
Castle Creek Biosciences has 4 investors. Key investors include Fidelity Investments, Paragon Biosciences, Horizon Tech Finance, and Valor Equity Partners.
Castle Creek Biosciences operates through Castle Creek Biosciences, Llc.
